click on circles to display study description...
anticoagulant, curative dose (n=191) vs. anticoagulant, prophylactic dose (n=191)
randomized controlled trial
full-dose anticoagulation
standard-dose prophylactic anticoagulation
COVID-19 severe or critically
open label
34 centers, United States
2x2 factorial deisgn with clopidogrel or no antiplatelet therapy; recruitment was stopped early in 03/2022 (∼50% planned recruitment) due to waning ICU-level COVID-19 rates
anticoagulant, curative dose (n=591) vs. anticoagulant, prophylactic dose (n=616)
randomized controlled trial
therapeutic anticoagulation with heparin
Therapeutic anticoagulation was administered according to local site protocols for the treatment of acute venous thromboembolism for up to 14 days or recovery
pharmacological thromboprophylaxis as per local usual care
COVID-19 severe or critically
open-blind
NCT02735707, NCT04505774, NCT04359277, NCT04372589
anticoagulation, intermediate prophylactic dose (n=276) vs. anticoagulant, prophylactic dose (n=286)
randomized controlled trial
intermediate-dose prophylactic anticoagulation
enoxaparin, 1mg/kg daily
standard-dose prophylactic anticoagulation
enoxaparin, 40mg daily
COVID-19 severe or critically
open-label
10 academic centers in Iran
2 × 2 factorial design comparing intermediate-dose vs standard-dose prophylactic anticoagulation and statin therapy vs matching placebo
powered by vis.js Network
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -
An extraction panel is open